Canadian Cancer Trials Group Bulletins


Two CCTG Trial in CCS's Top 10

Two CCTG trials -- CE.6 and MA.17R -- were included in the Canadian Cancer Society's list of the top 10 research impact stories for 2016.

Both trials were also included in the Plenary Session of the American Society of Clinical Oncology annual meeting earning the CCTG the unprecedented distinction of having two trials presented in the same ASCO Plenary Session. The papers that are chosen represent the best and most significant advances in cancer treatment and care with the greatest potential influence. Only four papers were chosen for the ASCO plenary session out of more than 5,000 submissions - to have two selected from one research organization is a rare achievement.

CE.6, A Randomized Phase III Study of Temozolomide and Short-Course Radiation vs. Short-Course Radiation Alone in the Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients, examined the use of the cancer drug temozolomide in the treatment of glioblastoma, an incurable form of brain cancer. The trial found that adding the drug to a shortened course of radiation therapy, followed by monthly maintenance doses, significantly improved the survival rate of elderly patients. The drug reduced the risk of death by 33 per cent, without loss of quality of life.

The co-principal investigators were Dr. James R. Perry (Sunnybrook Heath Sciences Centre) and Dr. Normand Laperriere (Princess Margaret Cancer Centre). Dr. Chris O'Callaghan was the Senior Investigator.

MA.17R, A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed with Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen, found that extending therapy with a commonly-used hormone drug called an aromatase inhibitor from five to 10 years in postmenopausal women with early breast cancer reduces the risk of recurrence by 34 per cent. The findings were published concurrently in the New England Journal of Medicine. The lead author was Dr. Paul Goss (Harvard Medical School). Dr. Wendy Parulekar was the CCTG Senior Investigator.

To see more, please use these links: